Pharminent

FDA approves AbbVie’s Parkinson’s disease therapy Juvmo

AbbVie’s Parkinson’s disease therapy Juvmo has won FDA approval, the first drug from AbbVie’s $8.7 billion takeover of Cerevel two years ago.

FDA approves Mirum and Incyte’s Atebrioz for FOP

The FDA approved Mirum Pharmaceuticals and Incyte’s Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva in patients aged 12 and above.

Daiichi Sankyo, MSD withdraw ifinatamab deruxtecan BLA in small cell lung cancer

Daiichi Sankyo and Merck & Co (MSD) voluntarily withdrew their biologics license application for ifinatamab deruxtecan (I-DXd) in adult patients with extensive-stage small cell lung cancer.

Study finds nanopore sequencing could aid inherited muscle disease diagnosis

A new study suggests long-read ‘nanopore’ sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.